Dihydroartemisinin Sensitizes Lung Cancer Cells to Cisplatin Treatment by Upregulating <scp>ZIP14</scp> Expression and Inducing Ferroptosis
Our findings suggest that combining dihydroartemisinin (DHA) with cisplatin (DDP) presents a promising strategy to overcome chemoresistance in lung cancer patients. Importantly, administering DHA during chemotherapy intervals could further optimize treatment outcomes, enhancing the overall efficacy of lung cancer chemotherapy.
Authors
- Jianjun Jiang (ORCID: https://orcid.org/0000-0001-9178-8988)
- Zhijie Chen
- Meijuan Dian (ORCID: https://orcid.org/0000-0003-3726-0909)
- Shuan Rao (ORCID: https://orcid.org/0000-0002-5268-7006)
- Zehao Zhou (ORCID: https://orcid.org/0000-0001-5485-5600)
- Haiyan Ge (ORCID: https://orcid.org/0000-0001-7808-2403)
- Qingyu Meng (ORCID: https://orcid.org/0000-0002-2176-593X)
- Yun Liang (ORCID: https://orcid.org/0000-0003-0799-0054)
- Zichao Li (ORCID: https://orcid.org/0000-0002-4679-1042)
- Ruihao Zhang
- Yujing He (ORCID: https://orcid.org/0000-0003-3574-2357)
- Junming He (ORCID: https://orcid.org/0000-0003-3261-4202)
- Zhuoying Yang (ORCID: https://orcid.org/0009-0004-3784-0043)
- Biying Men (ORCID: https://orcid.org/0009-0005-8689-1928)
- Xu Wu (ORCID: https://orcid.org/0000-0002-1845-9464)
- Tianbao Yan
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Nanfang Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/cam4.70271
- Citations
- 9
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.77
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province